| Autor: |
Muhsin, Hanan Y., Al-Humairi, Rasha M.A., Alshareef, Duraid Q.J., Ad'hiah, Ali H. |
| Zdroj: |
Egyptian Rheumatologist; Oct2022, Vol. 44 Issue 4, p351-355, 5p |
| Abstrakt: |
To expand our understanding of interleukin-22 (IL-22) role in the pathogenesis of ankylosing spondylitis (AS). The study included 99 AS male patients and 97 male controls. Serum IL-22 levels were determined using an enzyme-linked immunosorbent assay. The mean age of AS patients was 35.5 ± 9.6 years, with an age at onset of 32.1 ± 6.8 years and disease duration of 10.1 ± 6.2 years. The disease duration was <5 years in 19.2 %, 5–10 years in 43.4 % and >10 years in 37.4 %. HLA-B27 was positive in 54.5 %. Median (interquartile range) levels of IL-22 were significantly higher in patients than in controls (17.3; 12.8–20.2 vs 12.3; 8.3–15.8 pg/ml; p < 0.001). Serum IL-22 levels were significantly higher in patients with disease duration of 5–10 years compared to those with disease duration >10 years. IL-22 level tended to be higher in HLA-B27-negative patients compared to positive (p = 0.13). IL-22 was not associated to the disease activity or functional status. Serum IL-22 at a cut-off point of 13.4 pg/mL could significantly distinguish AS patients from controls (area under the curve = 0.76; p < 0.001). Age-adjusted multinomial logistic regression analysis demonstrated that individuals classified in the middle (OR = 3.4; p = 0.001) and upper (OR = 12.8; p < 0.001) tertiles of the IL-22 level range were more likely to develop AS. IL-22 levels significantly inversely correlated with the disease duration (r = −0.33; p = 0.001). IL-22 serum levels were up-regulated in the serum of AS patients. These levels were not affected by disease activity, while they showed a negative association with the disease duration. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect